Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site.

J Biol Chem

Department of Clinical Chemistry, Institute of Laboratory Medicine, Lund University Hospital, S-221 85 Lund, Sweden.

Published: July 1999

We have investigated the inhibition of the recently identified family C13 cysteine peptidase, pig legumain, by human cystatin C. The cystatin was seen to inhibit enzyme activity by stoichiometric 1:1 binding in competition with substrate. The Ki value for the interaction was 0.20 nM, i.e. cystatin C had an affinity for legumain similar to that for the papain-like family C1 cysteine peptidase, cathepsin B. However, cystatin C variants with alterations in the N-terminal region and the "second hairpin loop" that rendered the cystatin inactive against cathepsin B, still inhibited legumain with Ki values 0.2-0.3 nM. Complexes between cystatin C and papain inhibited legumain activity against benzoyl-Asn-NHPhNO2 as efficiently as did cystatin C alone. Conversely, cystatin C inhibited papain activity against benzoyl-Arg-NHPhNO2 whether or not the cystatin had been incubated with legumain, strongly indicating that the cystatin inhibited the two enzymes with non-overlapping sites. A ternary complex between legumain, cystatin C, and papain was demonstrated by gel filtration supported by immunoblotting. Screening of a panel of cystatin superfamily members showed that type 1 inhibitors (cystatins A and B) and low Mr kininogen (type 3) did not inhibit pig legumain. Of human type 2 cystatins, cystatin D was non-inhibitory, whereas cystatin E/M and cystatin F displayed strong (Ki 0.0016 nM) and relatively weak (Ki 10 nM) affinity for legumain, respectively. Sequence alignments and molecular modeling led to the suggestion that a loop located on the opposite side to the papain-binding surface, between the alpha-helix and the first strand of the main beta-pleated sheet of the cystatin structure, could be involved in legumain binding. This was corroborated by analysis of a cystatin C variant with substitution of the Asn39 residue in this loop (N39K-cystatin C); this variant showed a slight reduction in affinity for cathepsin B (Ki 1.5 nM) but >>5,000-fold lower affinity for legumain (Ki >>1,000 nM) than wild-type cystatin C.

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.274.27.19195DOI Listing

Publication Analysis

Top Keywords

cystatin
18
affinity legumain
12
legumain
11
cysteine peptidase
8
pig legumain
8
legumain human
8
inhibited legumain
8
cystatin papain
8
cystatin inhibited
8
inhibition mammalian
4

Similar Publications

Objective: This study aimed to explore the relationship between occupational noise exposure and renal dysfunction in male workers.

Methods: A total of 160 male workers (the number of people who met the inclusion criteria) who underwent health examinations in Qingdao Municipal Hospital from January 2023 to December 2023 were grouped into a noise group (80 cases) and a control group (80 cases) based on whether they engaged in noise work. We compared the differences in creatinine (CREA), cystatin C (CysC) and blood urea nitrogen (BUN) levels between the two groups.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

University of Tennessee, Knoxville, TN, USA.

Background: Cardiovascular-kidney-metabolic (CKM) health, a term recently defined by the American Heart Association, encompasses the interplay among metabolic, chronic kidney, and cardiovascular risk factors. We aimed to investigate the predictive significance of CKM disorders with the risk of cognitive decline and Alzheimer's disease (AD) and AD-related dementia (ADRD) mortality in a multiethnic population.

Method: We analyzed a cohort of 6,440 adults aged 45-84 who participated in the Multiethnic Study of Atherosclerosis, with a baseline survey conducted in 2000-2002, and were followed through to December 2015.

View Article and Find Full Text PDF

Background: Recent research reveals that Alzheimer's Disease blood-based biomarkers (BBB) are influenced by demographics as well as kidney function and comorbidities. Data on differences in BBBs by race and ethnicity are sparse. We examined whether racial/ethnic differences in BBBs persist after controlling for kidney function and comorbidities.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

L & J Bio, Co., Ltd, Seoul, Songpa-Gu, Korea, Republic of (South).

Background: Neurofibrillary tangles (NFTs), along with amyloid beta plaque, are neuropathological aggregates of Alzheimer's Disease (AD). Hyperphosphorylated tau is responsible for the NFTs formation and further neurodegeneration in AD. The hippocampal region and the entorhinal cortex (EC) have been a major focus of AD research because the deposits of hyperphosphorylated tau protein and NFT in these regions are correlated with memory deficits.

View Article and Find Full Text PDF

[Construction of prognostic prediction model for patients with sepsis-induced acute kidney injury treated with continuous renal replacement therapy].

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue

December 2024

Department of Urology, Fuyang People's Hospital, Fuyang 236000, Anhui, China. Corresponding author: Li Dongfeng, Email:

Objective: To explore the influencing factors of prognosis in patients with sepsis-induced acute kidney injury undergoing continuous renal replacement therapy (CRRT), and to construct a mortality risk prediction model.

Methods: A retrospective research method was adopted, patients with sepsis-induced acute kidney injury who received CRRT at Fuyang People's Hospital from February 2021 to September 2023 were included in this study. Collect general information, comorbidities, vital signs, laboratory indicators, disease severity scores, treatment status, length of stay in the intensive care unit (ICU), and 28-day prognosis were collected within 24 hours of patient enrollment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!